MA53548B1 - Formulations antiparasitaires de goût agréable - Google Patents

Formulations antiparasitaires de goût agréable

Info

Publication number
MA53548B1
MA53548B1 MA53548A MA53548A MA53548B1 MA 53548 B1 MA53548 B1 MA 53548B1 MA 53548 A MA53548 A MA 53548A MA 53548 A MA53548 A MA 53548A MA 53548 B1 MA53548 B1 MA 53548B1
Authority
MA
Morocco
Prior art keywords
tasting
pleasant
composition
antiparasitic formulations
animal
Prior art date
Application number
MA53548A
Other languages
English (en)
Other versions
MA53548A (fr
Inventor
Sachin Pundlik Kolhe
Supriya Gautam THAKUR
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67982187&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA53548(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MA53548A publication Critical patent/MA53548A/fr
Publication of MA53548B1 publication Critical patent/MA53548B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Fodder In General (AREA)

Abstract

La présente invention concerne une composition à mâcher dure au goût agréable comprenant une quantité thérapeutiquement efficace d'une isoxazoline pharmaceutiquement acceptable, une lactone macrocyclique stabilisée, une forme saline acceptable de pyrantel, au moins un aliment naturel d'origine animale, et au moins un excipient acceptable du point de vue vétérinaire; et des procédés de traitement ou de prévention d'une infection ou d'une infestation parasitaire chez un animal en ayant besoin au moyen de ladite composition.
MA53548A 2018-09-05 2019-09-03 Formulations antiparasitaires de goût agréable MA53548B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862727018P 2018-09-05 2018-09-05
PCT/US2019/049279 WO2020051106A1 (fr) 2018-09-05 2019-09-03 Formulations antiparasitaires de goût agréable
EP19769675.0A EP3846786B1 (fr) 2018-09-05 2019-09-03 Formulations antiparasitaires de goût agréable

Publications (2)

Publication Number Publication Date
MA53548A MA53548A (fr) 2021-07-14
MA53548B1 true MA53548B1 (fr) 2024-12-31

Family

ID=67982187

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53548A MA53548B1 (fr) 2018-09-05 2019-09-03 Formulations antiparasitaires de goût agréable

Country Status (27)

Country Link
US (1) US11896594B2 (fr)
EP (2) EP4487846A3 (fr)
JP (1) JP7241170B2 (fr)
KR (1) KR102554130B1 (fr)
CN (1) CN113038937A (fr)
AU (1) AU2019336663B2 (fr)
CA (1) CA3109543C (fr)
CL (1) CL2021000474A1 (fr)
DK (1) DK3846786T3 (fr)
ES (1) ES3002764T3 (fr)
FI (1) FI3846786T3 (fr)
HR (1) HRP20241712T1 (fr)
HU (1) HUE069712T2 (fr)
IL (1) IL281206B2 (fr)
LT (1) LT3846786T (fr)
MA (1) MA53548B1 (fr)
MD (1) MD3846786T2 (fr)
MX (1) MX2021002606A (fr)
NZ (1) NZ774180A (fr)
PH (1) PH12021550338A1 (fr)
PL (1) PL3846786T3 (fr)
PT (1) PT3846786T (fr)
RS (1) RS66315B1 (fr)
SI (1) SI3846786T1 (fr)
SM (1) SMT202400523T1 (fr)
WO (1) WO2020051106A1 (fr)
ZA (1) ZA202100950B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022066A1 (fr) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Compositions pharmaceutiques pour blépharite et encroûtement des paupières liés à demodex
AU2018385766B2 (en) 2017-12-15 2022-12-01 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
BR112021019931A2 (pt) * 2019-04-04 2021-12-07 Tarsus Pharmaceuticals Inc Parasiticidas isoxazolina sistêmicos para tratamento ou profilaxia de doença transmitida por vetor e viral
AU2021311722A1 (en) 2020-07-24 2023-02-02 Elanco Us Inc. Process for making an isoxazoline compound and intermediate thereof
US20230277448A1 (en) * 2020-09-03 2023-09-07 Elanco Tiergesundheit Ag Chewable formulations
EP4208157A1 (fr) * 2020-09-04 2023-07-12 Elanco Us Inc. Formulations palatables
KR20230162001A (ko) * 2021-03-11 2023-11-28 인 더 보울 애니멀 헬스, 인크. 갯과에서 진드기 감염을 방제하기 위한 경구용 갯과 사료 및 방법
KR20240051920A (ko) * 2021-06-25 2024-04-22 인 더 보울 애니멀 헬스, 인크. 고양잇과의 진드기 감염을 구제하기 위한 경구용 고양잇과 사료 및 방법
PE20250117A1 (es) * 2021-06-25 2025-01-16 Intervet Int Bv Composiciones veterinarias apetecibles
CN115671040B (zh) * 2021-07-21 2024-02-27 瑞普（天津）生物药业有限公司 一种控制动物寄生虫感染的外用制剂
CN115671288B (zh) * 2021-07-21 2024-05-10 瑞普（天津）生物药业有限公司 一种抗寄生虫复方软咀嚼药物制剂及其制备方法与应用
PE20231574A1 (es) 2023-02-24 2023-10-04 Agrovet Market S A Composicion farmaceutica que comprende fluralaner, moxidectina y praziquantel para el tratamiento de infestaciones parasitarias en animales menores

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258062T3 (es) * 2000-10-10 2006-08-16 Wyeth Composicion antihelmintica.
AU2006100657C4 (en) * 2006-05-15 2009-09-10 Wyeth Stabilised formulation
UA108641C2 (uk) * 2010-04-02 2015-05-25 Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
LT2811998T (lt) 2012-02-06 2019-02-25 Merial, Inc. Paraziticidinės peroralinės veterinarinės kompozicijos, apimančios sistemiškai veikiančius aktyviuosius agentus, būdai ir jų panaudojimas
EP2833866B2 (fr) * 2012-04-04 2024-11-27 Intervet International B.V. Produits pharmaceutiques mous à mâcher
ES2748631T3 (es) * 2012-09-07 2020-03-17 Zoetis Services Llc Combinaciones parasiticidas de isoxazolina espirocíclica
NZ708741A (en) * 2012-12-19 2019-11-29 Bayer Animal Health Gmbh Tablets with improved acceptance and good storage stability
ES2846820T3 (es) 2013-04-12 2021-07-29 Zoetis Services Llc Composición de lactonas macrocíclicas, levamisol, un aminoazúcar y un agente antiparasitario adicional
US20170354593A1 (en) * 2014-11-03 2017-12-14 Zoetis Services Llc Palatable chewable veterinary composition
WO2017106812A1 (fr) 2015-12-19 2017-06-22 First Time Us Generics Llc Formulations pharmaceutiques de comprimés mous à mâcher
RU2657508C1 (ru) 2017-07-04 2018-06-14 Александр Анатольевич Хахалин Комбинированное противопаразитарное средство для лечения и профилактики гельминтозов и арахноэнтомозов плотоядных животных

Also Published As

Publication number Publication date
KR102554130B1 (ko) 2023-07-12
AU2019336663A1 (en) 2021-03-11
SMT202400523T1 (it) 2025-01-14
DK3846786T3 (da) 2024-12-02
MD3846786T2 (ro) 2025-04-30
BR112021004218A2 (pt) 2021-05-18
ZA202100950B (en) 2024-09-25
EP3846786A1 (fr) 2021-07-14
NZ774180A (en) 2023-04-28
US20210220360A1 (en) 2021-07-22
PT3846786T (pt) 2025-01-08
CN113038937A (zh) 2021-06-25
KR20210039427A (ko) 2021-04-09
PH12021550338A1 (en) 2021-10-04
SI3846786T1 (sl) 2025-04-30
JP2022501329A (ja) 2022-01-06
FI3846786T3 (fi) 2025-01-14
CA3109543C (fr) 2023-05-23
IL281206B2 (en) 2025-08-01
RS66315B1 (sr) 2025-01-31
HRP20241712T1 (hr) 2025-02-14
EP4487846A3 (fr) 2025-03-19
US11896594B2 (en) 2024-02-13
EP4487846A2 (fr) 2025-01-08
WO2020051106A1 (fr) 2020-03-12
MX2021002606A (es) 2021-05-12
PL3846786T3 (pl) 2025-03-03
ES3002764T3 (en) 2025-03-07
IL281206B1 (en) 2025-04-01
HUE069712T2 (hu) 2025-04-28
LT3846786T (lt) 2025-01-10
IL281206A (en) 2021-04-29
CA3109543A1 (fr) 2020-03-12
JP7241170B2 (ja) 2023-03-16
AU2019336663B2 (en) 2023-09-14
EP3846786B1 (fr) 2024-11-13
CL2021000474A1 (es) 2021-07-19
MA53548A (fr) 2021-07-14

Similar Documents

Publication Publication Date Title
MA53548B1 (fr) Formulations antiparasitaires de goût agréable
Cembella Chemical ecology of eukaryotic microalgae in marine ecosystems
Austin et al. Aeromonadaceae representatives (motile aeromonads)
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
NO20052306L (no) Dispergerbare farmasoytiske blandinger.
Cronberg et al. The occurrence of toxic blue-green algae in Lake Ringsjön, southern Sweden, despite nutrient reduction and fish biomanipulation
EA200701113A1 (ru) Макролиды
FR3076997B1 (fr) Extrait obtenu a partir de plusieurs plantes pour son utilisation dans la prevention et/ou le traitement des maladies chroniques inflammatoires de l'intestin
Goulas et al. A structure-derived snap-trap mechanism of a multispecific serpin from the dysbiotic human oral microbiome
Ghimire et al. When micro drives the macro: a fresh look at disease and its massive contributions in the Hindu Kush-Himalaya
JP7835682B2 (ja) バイオフィルムの形成を妨害する為の且つバイオフィルム関連障害を処置する為の組成物
FR3081686B1 (fr) Composition alimentaire comprenant de la phycocyanine
El Hammed et al. Use of allicin as feed additive to enhance vaccination capacity of Clostridium perfringens toxoid in rabbits
Shofiqur et al. Effect of passive immunization by anti-gingipain IgY on periodontal health of dogs
MA41102A (fr) Compositions contenant de la curcumine à biodisponibilité améliorée
ATE427351T1 (de) Primaten t-lymphotrophische viren
Awad et al. Efficacy of ciprofloxacin and clove extract on bacterial infection of clarias gariepinus
UA157558U (uk) Спосіб підвищення імунорезистентності котів при респіраторних інфекціях
Singh et al. Sponataneous lesions of cryptococcosis in White Leghorn chicken
Gupta Factors affecting the virulence of Photobacterium damselae subsp. damselae to yellowtail kingfish (Seriola lalandi)
Kupferschmied Molecular basis and regulation of insect pathogenicity in plant-beneficial pseudomonads
PFISTER Copyright© 2018 C HIMONAS, S SOTIRAKI, E PAPADOPOULOS, K PFISTER
JOP20220097A1 (ar) كريزانليزوماب يحتوي على صياغات اجسام مضادة
Daigneault et al. Penicillin Concentrations in Serum and Milk Following Administration of Procaine Penicillin G By Different Route at Different Dosage
Johnson Development of resistance following reduced susceptibility in Methicillin-Resistant Staphylococcus aureus infection: case report